Replimune gives an update on RP1 Clinical Development Program in CSCC
Category: #health  | By Mateen Dalal  | Date: 2019-10-17 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Replimune gives an update on RP1 Clinical Development Program in CSCC

Cutaneous squamous cell carcinoma (CSCC) is the second most common form of skin cancer caused because of the uncontrolled growth of abnormal squamous cells. Currently, Libtayo is the only approved treatment in the Brazil and United States, and conditionally approved treatment in the Canada and European Union, for the treatment of locally advanced or metastatic CSCC.

Replimune Group Inc., a biotechnology company pioneering a new generation of oncolytic immuno-gene therapies, however, has reportedly announced that it has enrolled the first patient for its randomized, registration-directed, controlled Phase 2 clinical study of RP1.

The clinical study is being conducted in combination with Regeneron and Sanofi’s Libtayo® compared to Libtayo alone in patients who are suffering from CSCC.

Sources cite that initial data garnered from this clinical trial firmly supports the utility of RP1 in CSCC. Replimune has also announced its plan to begin another clinical trial of RP1 as monotherapy in organ transplant receiver with CSCC in early 2020.

According to Robert Coffin, Ph.D., CEO and President of Replimune, the company is delighted to announce the initiation of its first registration-directed clinical trial and data garnered for RP1 is strongly supportive.

Reportedly, the Phase 2 clinical study of RP1 is randomized, multi-center, and controlled clinical trial and is anticipated to register approximately 240 patients. Its main goal is to assess the response rate of RP1 with Libtayo against the response rate with Libtayo alone. This clinical study is conducted with Replimune’s collaboration agreement with Regeneron.

Reliable sources further claim that the full Phase 1 clinical efficacy, safety and biomarker data from this clinical trial, which Replimune expects will further support the overall clinical advancement strategy for RP1, is scheduled to be demonstrated at SITC (The Society For Immunotherapy of Cancer) Annual Meeting in National Harbor, Maryland on November 8, 2019.

Source Credit - https://www.biospace.com/article/releases/replimune-provides-update-on-rp1-clinical-development-program-in-cutaneous-squamous-cell-carcinoma/

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted

Microsoft investigates Teams and Outlook outage that left users disrupted

By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

By Mateen Dalal

Britishers who rely on the budget-friendly aisles of supermarkets reportedly saw the biggest increases in food prices in the months leading up to Christmas, significantly outpacing those for luxury as well as premium brands, as per a survey. Accor...

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

By Mateen Dalal

Sun Cable, the Singapore-based solar energy company, has reportedly entered voluntary administration, despite the financial support it received from billionaire investors. The company was supposed to be working on a A$30 billion (US$21 billion) solar...